Drug Trial Radar · NCT00348309
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Nov 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,496
Actual
Start
Jul 6, 2006
Primary completion
Jan 1, 2009
Study completion Jan 28, 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 4, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with the currently approved AD medication, Aricept (donepezil). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects their response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.
Conditions
- Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mgDrug
Rosiglitazone Extended Release 2mg OD
Rosiglitazone Extended Release 8mgDrug
Rosiglitazone Extended Release 8mg OD
PlaceboOther
Placebo
DonepezilOther
Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48Time frame: Baseline (Week 0) and Week 48
- Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4Time frame: Baseline (Week 0) and Week 48
Locations
249 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Litchfield Park, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Fresno, California
GSK Investigational Site
Rancho Mirage, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Sherman Oaks, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Delray Beach, Florida
GSK Investigational Site
Hallandale, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
St. Petersburg, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Hoffman Estates, Illinois
GSK Investigational Site
Fort Wayne, Indiana
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Glen Burnie, Maryland
GSK Investigational Site
Rockville, Maryland
GSK Investigational Site
Saint Paul, Minnesota
GSK Investigational Site
Lebanon, New Hampshire
GSK Investigational Site
Morristown, New Jersey
GSK Investigational Site
Nutley, New Jersey
GSK Investigational Site
Princeton, New Jersey
GSK Investigational Site
Stratford, New Jersey
GSK Investigational Site
Albany, New York
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Raleigh, North Carolina
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Providence, Rhode Island
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
South Ogden, Utah
Showing 40 of 249 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.